Efficacy of Early Ivermectin Administration in Acute Chikungunya Virus Infection: A Multicenter, Open-Label, Randomized Controlled Trial
Year: 2026
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: BACKGROUND: Acute and chronic joint pain is the hallmark of chikungunya virus (CHIKV) infection, often progressing to debilitating persistent joint pain. No approved antiviral therapy is available. We evaluated the clinical and virological efficacy of early ivermectin administration in acute CHIKV infection. METHODS: This open-label, randomized trial enrolled and randomized 127 adult patients with acute chikungunya within 72 hours of symptom onset in Thailand. Patients were assigned (1:1) to oral ivermectin (400 µg/kg/day for 3 days) plus standard of care or standard of care alone. Before the 1-month endpoint, 7 patients were lost to follow-up, leaving a finalized complete-case cohort of 120 participants (n = 60 per arm) for primary efficacy analysis. Co-primary outcomes were time to acute joint pain clearance and the proportion of patients with persistent joint pain at 1 month. FINDINGS: Early ivermectin significantly accelerated acute joint pain resolution compared to controls (median 3.5 days [IQR 2, 6] vs 12.0 days [IQR 8, 35]; adjusted hazard ratio (aHR) 3.65, 95% CI 2.28, 5.84; p < 0.0001). Ivermectin was associated with a 92% reduction in the odds of persistent joint pain at 1 month (6.6% vs 30%; adjusted odds ratio (aOR) 0.08, 95% CI 0.03, 0.21; p < 0.0001). It also shortened fever clearance (median 2.0 vs 5.0 days; p < 0.0001) and accelerated viral clearance by day 7. CONCLUSIONS: Early ivermectin intervention within 72 hours of symptom onset significantly accelerates clinical recovery, suppresses viral replication, and profoundly reduces persistent joint pain at 1 month. These findings position ivermectin as a promising, scalable therapeutic strategy against CHIKV. TRIAL REGISTRATION: ClinicalTrials.gov, NCT06259383 (Retrospectively registered on February 20, 2024 prior to thawing bio-banked samples for sequential assays, laboratory assay and final analysis). ClinicalTrials.gov identifier: NCT06259383..
Source: Emerging Microbes & Infections
Authors: Sarunyou Chusri, Smonrapat Surasombatpattana, Pisud Siripaitoon, Narongdet Kositpantawong, Siripen Kanchanasuwan, Porntip Intapiboon, Sorawit Chittrakarn, Nattapat Sangkakul, Nonthanat Tongsengkee, Tawin Khaimook, Thanaporn Hortiwakul, Boonsri Charoenmak, Sujinda Ruangchan, Watjanarat Nitchot, Phangard Neamrat, Butsaya Thaisomboonsuk, Wudtichai Manasatienkij, Piyawan Chinnawirotpisan, Taweewun Hunsawong, Stefan Fernandez
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,643
OpenAlex ID: W7233721701
